<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51997">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429258</url>
  </required_header>
  <id_info>
    <org_study_id>D1690L00026</org_study_id>
    <nct_id>NCT02429258</nct_id>
  </id_info>
  <brief_title>Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin</brief_title>
  <official_title>Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of Dapagliflozin on 24-hour Blood Glucose in Type 2 Diabetes Patients Inadequately
      Controlled With Either Metformin Or Insulin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effect of Dapagliflozin on 24-hour Blood Glucose in 92 Type 2 Diabetes Patients Inadequately
      Controlled With Either Metformin Or Insulin
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24-hour mean weighted glucose</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in 24-hour mean weighted glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the 24-hour mean amplitude of glucose excursion</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in the 24-hour mean amplitude of glucose excursion (MAGE; &quot;distance traveled&quot; arc length of the curve; and &quot;energy&quot;) using the CGM (continuous glucose monitoring) system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of time patients had plasma glucose measurements &lt;70 mg/dL, &gt;/= 70 mg/dL and &lt;/= 180mg/dL, and &gt;180mg/dL</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in proportion of time patients had plasma glucose measurements &lt; 70 mg/dL, &gt;/= 70 mg/dL and &lt;/= 180 mg/dL, and &gt;180 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 4-hour mean weighted postprandial glucose (PPG)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in 4-hour mean weighted PPG (after breakfast meal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fructosamine</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in fructosamine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2-hour mean weighted PPG</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in 2-hour mean weighted PPG after the standardized breakfast meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in 24-hour glucose profile</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Difference in 24-hour glucose profile during 7-day continuous glucose monitoring (CGM) assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin secretion</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in insulin secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in insulin sensitivity</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Type II Diabetes</condition>
  <arm_group>
    <arm_group_label>Farxiga with metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Farxiga with &gt;/=1500mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with metformin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with metformin &gt;/=1500mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Farxiga with insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Farxiga with insulin &gt;/= 30 units/day and up to 2 oral anti-diabetic (OAD) medications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with insulin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with insulin &gt;/= 30 units/day and up to 2 OAD medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Farxiga</intervention_name>
    <description>Farxiga 10mg/day</description>
    <arm_group_label>Farxiga with metformin</arm_group_label>
    <arm_group_label>Farxiga with insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo with metformin</arm_group_label>
    <arm_group_label>Placebo with insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin background therapy &gt;/= 1500mg/day</description>
    <arm_group_label>Farxiga with metformin</arm_group_label>
    <arm_group_label>Placebo with metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin &gt;/= 30 units</description>
    <arm_group_label>Farxiga with insulin</arm_group_label>
    <arm_group_label>Placebo with insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus (T2DM)

          -  Treated with either stable dose of metformin alone &gt; or = to 1500mg/day or stable
             dose of insulin &gt; or = to 30 units/day and up to 2OAD medications for at least 8
             weeks

          -  Hemoglobin A1c (HbA1c) 7.5% to 10.5% at screening

          -  Body mass index (BMI) &lt; or = to 45 kg/m2

        Exclusion Criteria:

          -  For patients who enter the study taking a stable dose of metformin, history of taking
             OAD medications other than metformin during the 8 weeks prior to screening or have
             been on insulin therapy within 1 year of screening

          -  For patients who enter the study taking insulin, history of taking any other therapy
             outside of the stable insulin and up to 2 OAD medications for 8 weeks prior to
             screening.

          -  Use of sulfonylureas during the 8 weeks prior to screening

          -  Prior exposure to dapagliflozin or any sodium-glucose co-transporter 2 (SGLT-2)
             inhibitor

          -  Ingestion of any medication know to affect glucose metabolism for &gt;7 consecutive days
             during the 3 months prior to Screening

          -  Ingestion of prescription or over the counter weight loss medication during 3 months
             prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 22, 2015</lastchanged_date>
  <firstreceived_date>April 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
